Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells

Diabetes

Volumn 54, Issue 7, 2005, Pages 2198-2205

  Passarelli, Marisa ^a   Tang, Chongren ^a   McDonald, Thomas O ^a   O'Brien, Kevin D ^a   Gerrity, Ross G ^b   Heinecke, Jay W ^a   Oram, John F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ADVANCED GLYCATION END PRODUCT; ALDEHYDE DERIVATIVE; APOLIPOPROTEIN A1; GLYCOALDEHYDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL CULTURE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IMMUNOHISTOLOGY; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; SWINE;

ACETALDEHYDE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; CHOLESTEROL; FIBROBLASTS; GLYCOSYLATION END PRODUCTS, ADVANCED; GLYOXAL; HUMANS; KINETICS; MACROPHAGES, ALVEOLAR; METHYLGUANIDINE; MICE; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; SKIN;

EID: 21344446514     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.7.2198     Document Type: Article

References (47)

1. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 59:8-13, 1979
2. Bierman EL: George Lyman Duff Memorial Lecture: Atherogenesis in diabetes. Arterioscler Thromb 12:647-656, 1992
3. Ginsberg HN: Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. Diabetes Care 14:839-855, 1991
4. Quintao EC, Medina WL, Passarelli M: Reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev 16:237-250, 2000
5. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA: High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation 74:1217-1225, 1986
6. Oram JF: HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol 23:720-727, 2003
7. Wang N, Tall AR: Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23:1178-1184, 2003
8. Singaraja RR, Brunham LR, Visscher H, Kastelein JJ, Hayden MR: Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol 23:1322-1332, 2003
9. Joyce C, Freeman L, Brewer HB Jr, Santamarina-Fojo S: Study of ABCA1 function in transgenic mice. Arterioscler Thromb Vasc Biol 23:965-971, 2003
10. Aiello RJ, Brees D, Francone OL: ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation. Arterioscler Thromb Vasc Biol 23:972-980, 2003
11. Assman G, von Eckardstein A, Brewer HB: Familial high density lipoprotein deficiency: Tangier disease. In The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, Eds. New York, McGraw-Hill, 1995, p. 2053-2072
12. Serfaty-Lacrosniere C, Civeira F, Lanzberg A, Isaia P, Berg J, Janus ED, Smith MP Jr, Pritchard PH, Frohlich J, Lees RS, Barnard GF, Ordovas JM, Schaefer EJ: Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 107:85-98, 1994
13. Oram JF, Lawn RM, Garvin MR, Wade DP: ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 275:34508-34511, 2000
14. Wellington CL, Walker EK, Suarez A, Kwok A, Bissada N, Singaraja R, Yang YZ, Zhang LH, James E, Wilson JE, Francone O, McManus BM, Hayden MR: ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest 82:273-283, 2002
15. Wang Y, Oram JF: Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J Biol Chem 277:5692-5697, 2002
16. Wang Y, Kurdi-Haidar B, Oram JF: LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J Lipid Res 45:972-980, 2004
17. Feng B, Tabas I: ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages mechanism involves enhanced ABCA1 degradation in a process requiring full NPC1 activity. J Biol Chem. 277:43271-43280, 2002
18. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1-9, 1999
19. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
20. Thornalley PJ, Langborg A, Minhas HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109-116, 1999
21. Wolff SP, Dean RT: Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 245:243-250, 1987
22. Glomb MA, Monnier VM: Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 270:10017-10026, 1995
23. Anderson MM, Hazen SL, Hsu FF, Heinecke JW: Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein: a mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 99:424-432, 1997
24. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW: The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104:103-113, 1999
25. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR: The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271:9982-9986, 1996
26. Thornalley PJ: Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification: a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 27:565-573, 1996
27. Sady C, Jiang CL, Chellan P, Madhun Z, Duve Y, Glomb MA, Nagaraj RH: Maillard reactions by alpha-oxoaldehydes: detection of glyoxal-modified proteins. Biochim Biophys Acta 1481:255-264, 2000
28. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 90:6434-6438, 1993
29. Requena JR, Ahmed MU, Fountain CW, Degenhardt TP, Reddy S, Perez C, Lyons TJ, Jenkins AJ, Baynes JW, Thorpe SR: Carboxymethylethanolamine, a biomarker of phospholipid modification during the maillard reaction in vivo. J Biol Chem 272:17473-17479, 1997
30. Mendez AJ, Oram JF, Bierman EL: Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J Biol Chem 266:10104-10111, 1991
31. Oram JF, Mendez AJ, Lymp J, Kavanagh TJ, Halbert CL: Reduction in apolipoprotein-mediated removal of cellular lipids by immortalization of human fibroblasts and its reversion by cAMP: lack of effect with Tangier disease cells. J Lipid Res 40:1769-1781, 1999
32. Mendez AJ, Anantharamaiah GM, Segrest JP, Oram JF: Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest 94:1698-1705, 1994
33. Oram JF, Albers JJ, Bierman EL: Rapid regulation of the activity of the low density lipoprotein receptor of cultured human fibroblasts. J Biol Chem 255:475-485, 1980
34. Gerrity RG, Natarajan R, Nadler JL, Kimsey T: Diabetes-induced accelerated atherosclerosis in swine. Diabetes 50:1654-1665, 2001
35. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, Wight TN, Chait A: Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 98:519-527, 1998
36. Suzuki LA, Poot M, Gerrity RG, Bornfeldt KE: Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. Diabetes 50:851-860, 2001
37. Vaughan AM, Oram JF: ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res 44:1373-1380, 2003
38. Wang N, Silver DL, Costet P, Tall AR: Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 275:33053-33058, 2000
39. Fitzgerald ML, Morris AL, Rhee JS, Andersson LP, Mendez AJ, Freeman MW: Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J Biol Chem 277:33178-33187, 2002
40. Hirsch J, Petrakova E, Feather MS: The reaction of some dicarbonyl sugars with aminoguanidine. Carbohydr Res 232:125-130, 1992
41. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34:10872-10878, 1995
42. Thornalley PJ, Yurek-George A, Argirov OK: Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 60:55-65, 2000
43. Thornalley PJ: Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem J 254:751-755, 1988
44. Seigneur M, Freyburger G, Gin H, Claverie M, Lardeau D, Lacape G, Le Moigne F, Crockett R, Boisseau MR: Serum fatty acid profiles in type I and type II diabetes: metabolic alterations of fatty acids of the main serum lipids. Diabetes Res Clin Pract 23:169-177, 1994
45. Hayden JM, Reaven PD: Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors. Curr Opin Lipidol 11:519-528, 2000
46. Uehara Y, Engel T, Li Z, Goepfert C, Rust S, Zhou X, Langer C, Schachtrup C, Wiekowski J, Lorkowski S, Assmann G, Von Eckardstein A: Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes 51:2922-2928, 2002
47. Albrecht C, Simon-Vermot I, Elliott JI, Higgins CF, Johnston DG, Valabhji J: Leukocyte ABCA1 gene expression is associated with fasting glucose concentration in normoglycemic men. Metabolism 53:17-21, 2004